Opinion|Videos|January 18, 2024
Updates on Combination Treatment Approaches with BTKi + Venetoclax
Expert faculty highlight key updates from trials evaluating combination therapy approaches using venetoclax plus a BTKi in the frontline setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option
3
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer
4
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
5